When it comes to improving health outcomes, representation matters! Learn how Johnson & Johnson is collaborating with leaders in the field of dermatology and striving to support diverse talent in dermatology practice and research to advance innovative solutions for patients.
Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…
Repibresib’s localized delivery minimizes systemic exposure while targeting inflammatory pathways, a novel approach for vitiligo management.
A comprehensive study finds no significant link between exposure to tobacco smoke and the severity or activity of atopic dermatitis in children and adolescents.
The results showed promising improvements in all endpoints with high patient satisfaction and no safety concerns.
After 8 weeks of use, the product showed improvements in skin sensitivity, transepidermal water loss, and skin corneum hydration.
This cohort study assesses the incidence of a second melanoma diagnosis after initial diagnosis among racial and ethnic minority populations.
Friday, January 10, 2025 12:30 – 1:00 PM ET CME/CNE/CPE/IPCE Virtual Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease in the United States,…
Explore the top headlines of the week including 2025 PDUFA dates, 2024 interview insights, and awareness dates to add to your calendar.
Find information about submitting and presenting abstracts at the 2025 AAD Annual Meeting.
This scoping review examines the impact of clinical information on the histopathologic diagnosis of melanocytic skin lesions.
